ABSTRACT Bio‐multifunctional high‐entropy alloys (BMHEAs) represent a frontier and early‐stage research area in biomedical materials, poised to revolutionize implantable devices amid the escalating demands of an aging population. Unlike conventional metallic implants, which frequently exhibit poor biocompatibility, high infection risks, and mechanical mismatches with host tissues—leading to complications like implant failure and revision surgeries—BMHEAs leverage their multi‐principal element composition to integrate superior properties such as enhanced biocompatibility, mechanical strength, antimicrobial activity, and controlled degradation. For instance, CoCrFeNiMn‐based BMHEAs have demonstrated exceptional corrosion resistance and osteogenic promotion in vitro, outperforming titanium alloys by reducing bacterial adhesion by up to 90% while fostering better cell proliferation. Similarly, TiZrHfNbTa BMHEAs exhibit tunable Young's modulus close to that of cortical bone (10–30 GPa), minimizing stress shielding and improving long‐term osseointegration, as evidenced by animal studies showing accelerated bone healing compared to stainless steel implants. These examples underscore BMHEAs’ immense potential to address clinical challenges, including infection control and tissue integration. Despite ongoing hurdles like predictive design and in vivo validation, the rapid progress in computational screening positions BMHEAs as transformative candidates for next‐generation implants, promising enhanced patient outcomes and reduced healthcare burdens.
Xu et al. (2026) studied this question.